ToplineNovo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company’s weight loss and diabetes drugs Wegovy and Ozempic, the Danish firm said Monday.The Danish company said it plans to spend $6.8 billion on production this year. NurPhoto via Getty Images Key FactsNovo Nordisk said the funds will be used to develop a 1.4 million square foot facility in Clayton, North Carolina, where the company’s medicines—like Ozempic and W ...